(redirected from Neuraminidase inhibitor)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
Related to Neuraminidase inhibitor: Oseltamivir, amantadine, Tamiflu, Zanamivir
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Antonyms for inhibitor

a substance that retards or stops an activity

References in periodicals archive ?
Director of the Office of Antimicrobial Products at the FDA, Edward Cox, said, "Rapivab is the third neuraminidase inhibitor approved by the FDA to treat flu infection, but the first approved as an intravenous formulation.
Oseltamivir, the neuraminidase inhibitor, and amantadine, an M2 ion channel inhibitor, face 90% and 100% resistance respectively, in some areas.
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
So basically all that physicians had available early on were the oral neuraminidase inhibitor oseltamivir (Tamiflu) and the inhalation-only formulation of zanamivir (Relenza), another neuraminidase inhibitor.
Tamiflu is an oral neuraminidase inhibitor that is active against all strains of influenza A and B tested.
Writing in the British Medical Journal (BMJ), they said just one mutation could lead to a flu strain resistant to neuraminidase inhibitors or ion channel inhibitors.
has signed an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor.
Peramivir is a neuraminidase inhibitor, as are the currently used drugs Tamiflu and Relenza; however, its manufacturer claims that this drug will be easier and cheaper to produce than available drugs.
Zanamivir, like oseltamivir, is a neuraminidase inhibitor that is effective against both influenza A and influenza B.
The drug - at this stage known only as a neuraminidase inhibitor - acts by blocking the spread of the virus once it has invaded the body.
A neuraminidase inhibitor is a true antiviral agent in that it works on all strains by affecting how the virus behaves.
BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout.
InavirA by Daiichi Sankyo is a long-acting neuraminidase inhibitor developed and manufactured in Japan.
50]s (concentration of neuraminidase inhibitor required to reduce enzyme activity by 50%) with all 4 NAIs, similar to results for the drug-sensitive seasonal influenza A viruses used as controls (Table 1).
In the six trials totaling nearly 2,000 subjects in which administration of antibiotics was an end point, treatment with a neuraminidase inhibitor conferred a 23% reduction in the use of antibiotic therapy, he continued.